Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Fas 1-klinisk prövning för att utvärdera säkerhet, effekt och farmakokinetik hos IPS101A hos patienter med Parkinsons sjukdom

3 november 2026 uppdaterad av: Innopeutics Corporation

Dose-Escalation, Single-Center, Open-label Fas 1-klinisk prövning för att utvärdera säkerheten, effektiviteten och farmakokinetiken av adeno-associerat virus (AAV) genterapiprodukten IPS101A hos patienter med Parkinsons sjukdom i Hoehn-Yahr-stadium 4-5, diagnosticerade för mer än 10 år och obehandlade med all tillgänglig monoterapi eller kombinationsterapi

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

6

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Seoul, Sydkorea
        • Rekrytering
        • Severance Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

50 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
  2. Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
  3. Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
  4. Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
  5. Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.

Exclusion Criteria:

  1. Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
  2. Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
  3. Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
  4. Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
  5. Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
  6. Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Low dose (1.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

Experimentell: High dose(2.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety Evaluation: dose-limiting toxicity (DLT)
Tidsram: Baseline to Week 8

Frequency and proportion of subjects who developed dose-limiting toxicity (DLT)

Baseline to Week 8
Safety Evaluation: Severity and frequency of reported adverse events
Tidsram: Baseline to Week 52

Assess severity and frequency of reported adverse events

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
Tidsram: Baseline to Week 52

The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
Tidsram: Baseline to Week 52

The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur.

Baseline to Week 52

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
Tidsram: Baseline to Weeks 4, 12, 24, 36, and 52.

Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease.

Baseline to Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Hoehn & Yahr stage (defined on/off)
Tidsram: Weeks 1, 4, 12, 24, 36, and 52.

This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease.

Weeks 1, 4, 12, 24, 36, and 52.
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
Tidsram: Weeks 4, 12, 24, 36, and 52.

This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease.

Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
Tidsram: Weeks 4, 12, 24, 36, and 52

The scale consists of 800 points, and a higher score indicates a lower quality of life.

Weeks 4, 12, 24, 36, and 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
Tidsram: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
Tidsram: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
Tidsram: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using ELISA

Baseline to Week 52
Assessment of AAV9 shedding in biological specimens-urine
Tidsram: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 maj 2026

Primärt slutförande (Beräknad)

30 juni 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

17 november 2025

Först inskickad som uppfyllde QC-kriterierna

19 januari 2026

Första postat (Faktisk)

27 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera